DBV Technologies Stock to Reverse Split on Friday, November 29th (NASDAQ:DBVT)

DBV Technologies S.A. (NASDAQ:DBVT) shares are going to reverse split before the market opens on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

DBV Technologies Trading Up 5.3 %

Shares of NASDAQ DBVT opened at $0.59 on Friday. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.14. The company has a market cap of $56.92 million, a price-to-earnings ratio of -0.66 and a beta of 0.66. The stock’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $0.89.

Wall Street Analyst Weigh In

Several research firms recently commented on DBVT. HC Wainwright raised their target price on DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th. Finally, StockNews.com initiated coverage on DBV Technologies in a report on Thursday. They set a “hold” rating on the stock.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.